MSU 4.1-633 Docket No.

PATENT

## NITED STATES PATENT AND TRADEMARK

2 2003 Application No.: 0 10/037,311 Group No.::

Natasha V. Raikhel and Kenneth G. Keegstra

1638

Anne R. Kubelik

Fied: November 9, 2001 Examiner: Xyloglucan Fucosyltransferases

**Assistant Commissioner for Patents** Washington, D.C. 20231

## SUBMISSION OF PROPOSED DRAWING AMENDMENT RECEIVED FOR APPROVAL BY EXAMINER (37 C.F.R. 1.123)

Attached please find

SEP 0 8 2003

(check applicable items):

**TECH CENTER 1600/2000** 

a sketch in permanent ink,

a copy of the original drawing(s) with red ink markings,

showing the proposed changes to the drawing(s) in this application, for which the approval of the Examiner is requested.

Reg. No.: 20,931

Ian C. McLeod (type or print name of practitioner)

Tel. No.: (517) 347-4100

<u>2190 Commons Parkway</u>

P.O. Address

Customer No.:

21036

Okemos, Michigan

NOTE: 37 C.F.R. § 1.121(a)(3)(ii) indicates that "Where a change to the drawings is desired, a sketch in permanent ink showing proposed changes in red, to become part of the record, must be filed for approval by the examiner and should be in a separate paper."

NOTE: While drawings submitted under §§ 1.81, 1.83-1.85, 1.152, 1.165, 1.174, and 1.437 may not be filed by facsimile, proposed drawing corrections for approval may be submitted by facsimile transmission. Notice of Oct. 15, 1993, 58 Fed. Reg. 54,494-54,504, at 54,495.

## CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

## **MAILING**

☑ deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: 8/28/2003

Tammi L. Taylor

(type or print name of person certifying)

(Submission of Proposed Drawing Amendment for Approval by Examiner (37 C.F.R. 1.123) [9-16]—page 1 of 1)

AVAILABLE COPY